Compare LAW & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | ESPR |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.2M | 731.9M |
| IPO Year | 2021 | 2013 |
| Metric | LAW | ESPR |
|---|---|---|
| Price | $3.63 | $3.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $8.00 | ★ $8.75 |
| AVG Volume (30 Days) | 510.6K | ★ 17.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.58 | ★ 60.71 |
| EPS | N/A | ★ N/A |
| Revenue | $156,849,000.00 | ★ $403,135,000.00 |
| Revenue This Year | $11.23 | N/A |
| Revenue Next Year | $10.60 | $12.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 8.29 | ★ 21.31 |
| 52 Week Low | $2.45 | $0.76 |
| 52 Week High | $9.11 | $4.18 |
| Indicator | LAW | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 42.86 | 70.78 |
| Support Level | $3.30 | $2.37 |
| Resistance Level | $4.94 | $3.18 |
| Average True Range (ATR) | 0.35 | 0.04 |
| MACD | -0.08 | 0.05 |
| Stochastic Oscillator | 14.18 | 96.38 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.